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The insulin-like growth factors (IGFs) are 7-kDa polypeptides that share structural
homology with proinsulin.
1 These proteins have growth-promoting properties in
numerous tissues and are unable to suppress their bioactivity with anti-insulin
antibodies.
1,2 Both IGF-I and II are mitogens and IGF-II is much more active
during prenatal life than IGF-I.
3 IGF-I may be related to cognitive performance
4-8
and neoplasia,
3,9-23 and acts as a peripheral neuroactive signal participating not only
in protection against injury, but also in normal brain function. Declining levels of
serum IGF-I during aging may contribute to age-associated cognitive loss. IGF-I
may promote cell cycle progression and inhibition of apoptosis either by directly
associating with other growth factors or indirectly by interacting with other
molecular systems which play an established role in carcinogenesis and cancer
promotion, such as steroid hormones and integrins.
15 Experimental and clinical
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studies suggest that increased serum levels of IGF-I and/or
altered levels of their binding proteins are associated with
increased risk of developing several malignancies.
9-12,14-23
However, patients with hepato-cellular carcinoma were
found to have lower IGF-I levels than those without
hepatocellular carcinoma.
13 Inap-propriate expression of the
GH-IGF-I axis may contribute to cancer development.
19 In
extracellular tissues, circulating IGF-I is carried by a family
of insulin-like growth factor binding proteins: more than
75% of circulating IGF-I is carried in a trimeric complex
composed of IGF binding protein-3 (IGFBP-3), the main
IGFBP in the serum, and a liver-derived glycoprotein known
as the acid-labile subunit.
24 IGF-I and IGFBPs are produced
in several tissues, however, are mainly synthesized in the
liver.
25,26 IGF-I, IGFBP-3, and acid-labile subunit can be
induced by human growth hor-mone (GH) and are affected
by states of excess or deficiency of GH.
27 Besides GH,
circulating IGF-I concentrations can also be affected by
many factors.
3 Aging is an indirect deter-minant to affect the
circulating IGF-I concentrations through its influence on GH-
IGF-I axis.
3 The activity of the  GH-IGF-I axis undergoes an
age-related reduction, and both spontaneous GH secretions
and IGF-I values in the elderly subjects are frequently
low.
28-31 Estrogens and androgens are not only the direct
determinants to affect the circulating IGF-I concentrations,
but also indirect determinants through their influence on
GH-IGF-I axis.
3 Serum concentrations of estrogens in post-
menopausal women are quite different from women with
menstruation. Serum concentrations of androgens in men of
over 50 age years may be different from men with age less
than 50 years.
32-36 Therefore, middle aged adults will
undergo remarkable changes in their sex hormones which
may have the possibility to influence the serum
concentrations of IGF-I. The serum concentrations of
IGFBP-3 and GH may also be changed with IGF-I variation.
Age-related changes in body composition, function and
metabolism may be related to changes in serum concen-
trations of IGF-I, IGFBP-3, and GH.
28,29 Women are known
to have an increased incidence of age-related diseases such
as osteoporosis, Alzhelmer’s disease, urinary incontinence,
and coronary atherosclerosis after menopause.
37 Although
changes in female sex hormones may be the main reason,
37
changes in serum IGF-I, IGFBP-3, and GH concentrations
may also play some roles.
3,28,29 Rapid increases in the inci-
dence of age-related diseases in women is not observed in
men. This could be due to the fact that sex hormonal changes
proceed gradually in men compared to the sudden and fast
changes that occur in women.
37 Therefore, the patterns of
changes in serum IGF-I, IGFBP-3, and GH concentrations
in men may be quite different from women. However, the
influence of gender on serum concentrations of IGF-I,
IGFBP-3, and GH in middle and old aged subjects has not
yet been well studied. The purpose of this prospective study
was to clarify this issue. Our results may contribute to under-
standing the influence of gender on the aging process.
Subjects
A total of 60 healthy volunteers (male 35, female 25, age
range 36-70 years) were divided into ≤ 50 years and > 50
years groups, based on the gender (Table 1). All female
subjects were questioned for their menstrual status at the
start of the study. Female subjects without menstruation for
at least one year were defined as post-menopausal. Female
subjects > 50 years with menstrual cycle or ≤ 50 years
without menstrual cycle and subjects with surgical history
in gynecologic field were not included. None of the female
volunteers had been treated by any hormone therapy. All
female volunteers with age more than 50 years were post-
menopause. None of the volunteers had history of cardiac
disease, hypertension, pulmonary disease, diabetes mellitus,
renal disease, or liver disease. All volunteers received health
examinations. The renal and hepatic function, blood cell
counts, alpha-fetoprotein, tissue polypeptide antigen,
carcinoembryonic antigen, carbohydrate antigen 19-9, car-
bohydrate antigen 125, carbohydrate antigen 153, and
thyroid stimulating hormones were all within their normal
limits. None of the volunteers was positive for hepatitis B
surface antigen or hepatitis C antibody. This study was
approved by the Institutional Review Board of Kaohsiung
Medical University Hospital (ClinicalTrials.gov NCT0067
9692). Each volunteer gave informed consent to participate
in this study.
Methods
All volunteers fasted overnight for blood sampling. The
serum used for the study was collected by centrifugation
(3,500 g, 20 minutes) of blood immediately drawn from the
MATERIALS AND METHODS
Table 1.Distribution of Age in Sixty Volunteers
Age (yrs) Male (n) Female (n) Total (n)
≤50 11  (45.4  ± 4.2, 37 - 50, 47) 12 (43.3 ± 4.2, 36 - 50, 43.5) 23
> 50 24 (57.9 ± 5.53, 51 - 70, 56) 13 (55.5 ± 4.3, 51 - 63, 54) 37
Total 35 (53.9 ± 7.9*, 37 - 70, 54) 25 (49.6 ± 7.5*, 36 - 63, 51) 60
Parentheses indicate the mean, standard deviation, range, and median values of age. 
*p< 0.05.volunteer, and was stored at -20˚C for further investigation.
Serum values of IGF-I, IGFBP-3, and GH were determined
by a solid phase two-site immunoradiometric assay using
DSL-2800 ACTIVE
® Non-Extraction IGF-I IRMA Kit,
DSL-6600 ACTIVE
® IGFBP-3 IRMA Kit (Diagnostic
Systems Laboratories Inc, Webster, TX, USA), and CIS bio
international hGH-RIACT kit (CIS bio international, Bagnols
sur Cèze, France), respectively. The detection limit for IGF-I
by this method was 2.06 ng/mL, and there was no cross-
reaction with IGF-II, GH and insulin. The IGFBP-3
determined by our method was the total amount of IGFBP-3
which is the sum of intact and fragmented IGFBP-3. The
detection limit for IGFBP-3 by this method was 0.5 ng/mL,
and there was no cross-reaction with IGF-I, IGFBP-2 and
IGFBP-5. The detection limit for the GH was 0.03 µIU/mL.
The whole procedures for IGF-I, IGFBP-3 and GH
determinations were performed by a same person to avoid
inter-operator bias. The coefficient of variation values of intra-
assay for the operator were 6.2%, 0.4% and 0.4% at IGF-I
mean values (calculation from three determinations) of 34.01,
341.66 and 1181.10 ng/mL; 2.0%, 1.3% and 3.7% at IGFBP-
3 mean values of 404.67, 2235.3 and 4511.3 ng/mL; and
0.3%, 1.6% and 0.5% at GH mean values of 0.26, 14.54 and
67.29 µIU/mL, respectively. The coefficient of variation
values of inter-assay for the kits were 2.8%, 5.5% and 1.1%
at IGF-I mean values (calculation from 3 determinations of 1
sample by each kit) of 35.76, 362.72 and 1189.6 ng/mL,
1.1%, 1.9% and 0.5% at IGFBP-3 mean values of 406.0,
2212.6 and 4398.0 ng/mL; and 3.2%, 2.2% and 4.4% at GH
mean values of 0.28, 14.97 and 71.29 µIU/mL, respectively.
Statistical analysis
Data were expressed as mean ± standard deviation (SD).
The 2-tailed t-test was used to analyze the significance of
any difference between 2 means. Correlation analysis was
investigated by the calculation of a correlation coefficient
(r). Statistical significance was defined as p< 0.05.
IGF-I
IGF-I showed a significantly negative correlation with age in
1) total volunteers (r = -0.51,  p < 0.0001), 2) male volunteers
(r = -0.38,  p < 0.05), and 3) female volunteers (r = -0.62,  p <
0.001). There was no difference in IGF-I values between male
and female volunteers, and between male volunteers with ages
≤ 50 years and > 50 years. Female volunteers with ages > 50
years showed a significant reduction in IGF-I values than
female volunteers with ages ≤50 years (p< 0.01) (Table 2).
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RESULTS
Table 2.Serum IGF-I, IGFBP-3 and GH Values, and IGF-I/IGFBP-3 Molar Ratio, GH/IGF-I and GH/IGFBP-3 Ratios
Male Total (n = 35) Female Total (n = 25)
≤ 50 yrs (n = 11) ≤50 yrs ( n = 12)
> 50 yrs (n = 24) > 50 yrs (n = 13)
IGF-I (ng/mL) 338.6017 ± 82.16811 374.2924 ± 133.7389
362.4264 ± 108.4101 446.5658 ± 126.0089*
327.6821 ± 66.89427 307.5785 ± 105.6978*
IGFBP-3 (ng/mL) 5465.689 ± 821.3623
� 6618.004 ± 1324.696
�
5523.818 ± 479.7625
� 6849.392 ± 1435.811
�
5439.046 ± 945.9686
§ 6404.415 ± 1231.633
§
GH (µIU/mL) 1.972657 ± 4.257462 3.1884 ± 5.173602
1.081818 ± 1.40489 1.845 ± 2.298207
2.380958 ± 5.038183 4.428462 ± 6.724588
IGF-I/IGFBP-3 molar ratio  0.233418 ± 0.058556 0.211439 ± 0.065165
0.244529 ± 0.074044 0.247667 ± 0.069411
|
0.228326 ± 0.050979 0.177998 ± 0.039404
| ||
GH/IGF-I ratio (µIU/nmol) 45.59997 ± 94.21267 71.0787 ± 125.3425
29.27364 ± 47.57436 29.86122 ± 35.37853
53.08288 ± 109.3212 109.1256 ± 164.3323
GH/IGFBP-3 ratio (µIU/nmol) 9.362168 ± 18.93123 14.12639 ± 24.10989
5.622812 ± 7.328325 7.677116 ± 9.894097
11.07604 ± 22.28663 20.07956 ± 31.50955
Data were expressed as mean ± standard deviation (SD). The 2-tailed t-test was used to analyze the data. 
IGF-I, insulin-like growth factors-I; IGFBP-3, insulin-like growth factor binding protein-3; GH, growth hormone. 
*





IGFBP-3 did not show correlation with age in total, male and
female volunteers. Female volunteers showed significantly
higher IGFBP-3 values than male volunteers. There was no
significant difference in IGFBP-3 values between male or fe-
male volunteers with ages ≤50 years and > 50 years (Table 2).
GH
The variation of GH values was very large in male and
female volunteers. GH did not show correlation with ages
in total, male and female volunteers. There was no difference
in GH values between the male and female volunteers, and
between male or female volunteers with ages ≤ 50 years
and > 50 years (Table 2).
Correlation and molar ratio between IGF-I and IGFBP-3
There was a significantly positive correlation between IGF-I
and IGFBP-3 values in 1) total volunteers (r = 0.46,  p <
0.001), 2) volunteers with ages ≤50 years (r = 0.46,  p< 0.05),
3) volunteers with ages > 50 years (r = 0.41,  p< 0.05), 4) total
female volunteers (r = 0.52,  p < 0.01), and 5) female volun-
teers with ages > 50 years (r = 0.64,  p < 0.05). Male
volunteers and female volunteers with ages < 50 years did not
show correlation between IGF-I and IGFBP-3 values. IGF-
I/IGFBP-3 molar ratio showed a significantly negative
correlation with age in 1) total volunteers (r = -0.35,  p< 0.01),
and 2) female volunteers (r = -0.64,  p < 0.001). Male volun-
teers did not show correlation between IGF-I/IGFBP-3 molar
ratio and age. Women > 50 years showed a smaller IGF-
I/IGFBP-3 molar ratio (0.177998 ± 0.039404) than men of
same age group (0.228326 ± 0.050979,  p< 0.01) and women
< 50 years (0.247667 ± 0.069411,  p< 0.01) (Table 2).
Correlation and ratio between GH and IGF-I
There was no correlation between GH and IGF-I values in
1) total volunteers, 2) total male or female volunteers, 3)
male or female volunteers with ages  ± 50 years, and 4) male
or female volunteers with ages > 50 years. GH/IGF-I ratio
(µIU/nmol) showed a significantly positive correlation with
age in 1) total volunteers (r = 0.27,  p < 0.05), and 2) female
volunteers (r = 0.49,  p < 0.05). There was no difference in
GH/IGF-I ratio (µIU/nmol) between 1) total male and female
volunteers, 2) male and female volunteers with ages < 50
years, 3) male and female volunteers with ages > 50 years,
and 4) male or female volunteers with ages  ≤ 50 years and
> 50 years (Table 2).
Correlation and ratio between GH and IGFBP-3
There was a significantly positive correlation between GH
and IGFBP-3 values in 1) total male volunteers (r = 0.39,  p
< 0.05), and 2) male volunteers with ages > 50 years (r =
0.42,  p < 0.05). GH/IGFBP-3 ratio (µIU/nmol) showed a
significantly positive correlation with age in female vol-
unteers (r = 0.40,  p < 0.05). There was no difference in
GH/IGFBP-3 ratio (µIU/nmol) between 1) total male and
female volunteers, 2) male and female volunteers with ages
≤ 50 years, 3) male and female volunteers with ages > 50
years, and 4) male or female volunteers with ages ≤ 50
years and > 50 years (Table 2).
Correlation and ratio between GH and IGF-I/IGFBP-3
molar ratio
There was no correlation between GH values and IGF-
I/IGFBP-3 molar ratios in 1) total volunteers, 2) total male
and female volunteers, 3) male or female volunteers with
ages ≤ 50 years, and 4) male or female volunteers with ages
> 50 years. The ratios of GH values to IGF-1/IGFBP-3
molar ratios did not show correlation with age in total, male
and female volunteers.
Circulating IGF-I concentrations can be affected through
direct determinants such as protein-calorie intake, catabolic
stressors, thyroxine, insulin, binding affinity of acid-labile
subunit for IGF-I/IGFBP-3, zinc, parathyroid hormone,
parathyroid hormone-related peptide, and platelet-derived
growth factor.
3 Estrogens, androgens, adrenal androgens
and inflammatory cytokines are not only the direct deter-
minants to affect the circulating IGF-I concentrations, but
also indirect determinants through their influence on GH-
IGF-I axis.
3 Aging, body fat, and exercise are indirect deter-
minants to affect circulating IGF-I concentrations through
GH-IGF-I axis.
3 Serum IGF-I concentrations can be meas-
ured by different immunoassays.
38 The data obtained by our
method are higher than those by other immunoassays (RIA-
NICHOLS, ICMA-IMMULITE and IRMA-IMMUNOT-
ECH methods).
38 However, the difference in methodology
will not influence the clinical application of serum IGF-I
measurement.
38 Comparison of our results with other
studies should consider this difference. In the present study,
serum IGF-I values showed a significantly negative correla-
tion with age. This correlation was more prominent in
female volunteers than in male volunteers. However, there
was no significant difference in serum IGF-I values between
male and female volunteers. This result was in accordance
with one previous study,
38 but different from the study with
elderly subjects (mean age 71.6 years) in which serum IGF-
I was inversely correlated with age only in men, and men
had higher IGF-I values than women.
39 The discrepancy
may be due to small sample size in the present study or dif-
ference in subjects studied. Our subjects included both
women with and without menstruation. Serum IGF-I values
will significantly reduce in post-menopausal women as
shown in our results. Estradiol is known to stimulate IGF-I
Chiou-Meei Lin, et al.
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DISCUSSIONsynthesis and secretion from nonhepatic tissue.
29 Decrease
of estradiol in post-menopausal women may be responsible
for the decrease of IGF-I in this population. GH is known to
be an important factor to influence the circulating IGF-I
concentrations. However, GH did not show a significant
correlation with age in both male and female volunteers.
This result was in accordance with the previous study using
healthy subjects (30-60 years).
40 The releasable pool of GH
is generally preserved during the human life span.
41 This
may be the explanation for the lack of correlation between
GH values and age in our study. No significant correction
between serum IGF-I and GH values in the present study
indicates that GH is not an important determinant for the
serum IGF-I values in healthy middle and old age subjects.
Aging with prominent changes in sex hormones caused by
menopause may be the main determinant for the regulation
of IGF-I in middle and old age women. In contrast to female
volunteers, the factor of age over 50 years in male volunteers
did not show significant influence on IGF-I levels. The fact
that changes of androgens in men are not so clear-cut like
menopause in female may be the explanation.
37
The GH/IGF-I and GH/IGFBP-3 ratios represent how
much concentrations of GH are required to maintain the
serum concentrations of IGF-I and IGFBP-3. Increase of
GH/IGF-I and GH/IGFBP-3 ratios indicates that the
sensitivity of IGF-I and IGFBP-3 production to GH stimu-
lation decreases. Although there was a positive correlation
between GH/IGF-I ratio and age in all volunteers, this
correlation was observed in the female volunteers, but the
degree of this correlation was weak, indicating the trend of
progressive hypoactivity of GH to stimulate IGF-I
secretion with age in middle and old age women, but not in
men. Estrogen can regulate not only GH secretion at the
hypo-thalamic and pituitary level, but also can affect GH
action at the level of the GH receptor expression and
function.
42 Estrogen has been shown to inhibit Janus
kinase/signal transducer and activator of transcription
signaling by GH via the induction of suppressor of
cytokine signaling-2.
42 Estrogen provides one explanation
for the relative GH resistance observed in women.
42,43
Women are in a state of persistent estrogen-modulated GH
resistance for a long time
43 which may cause progressive
hypoactivity of GH to stimulate IGF-I secretion with age.
Although the correlation was weak, GH/IGFBP-3 ratio
also increased with age, similar to GH/IGF-I ratio with age
in female volunteers. Since both IGF-I and insulin are
necessary for maintenance of normal IGFBP-3 production
and IGF-I directly regulates synthesis of IGFBP-3,
44
increase of GH/IGFBP-3 ratio with age may be via
hypoactivity of GH to stimulate IGF-I secretion.
The bioavailability of IGF-I to the tissues is influenced
by serum IGFBP concentrations as well as IGFBP
proteolytic activity. The IGF-I/IGFBP-3 molar ratio can
reflect theoretically free, biologically active IGF-I.
29
Decreases in this ratio suggests reduction of IGF-I
activity.
45,46 Although the present study showed that female
volunteers had significantly higher IGFBP-3 values than
male volunteers, there was no significant difference in
IGF-I/IGFBP-3 molar ratio between male and female
volunteers with age ≤ 50 years. Since there was no
correlation between IGFBP-3 and age, significant
decreases of IFG-I in post-menopausal women caused
significant reduction of IGF-I/IGFBP-3 molar ratio in this
group. Post-menopausal women have reduced biologically
active IGF-I. On the other hand, only women volunteers
showed a positive correlation between serum IGF-I and
IGFBP-3 values. Although female volunteers with ages ≤
50 years did not show this correlation, small sample size
may be the explanation. However, there was a significant
correlation between serum IGF-I and IGFBP-3 values in
post-menopausal women, even though the sample size was
small. This indicates that the correlated secretions between
IGF-I and IGFBP-3 become more obvious in post-meno-
pausal women than women with menstruation.
Only male volunteers showed a significantly positive
correlation between GH and IGFBP-3 values. However,
this correlation was actually observed in those with ages > 50
years. This suggests that IGFBP-3 secretion is significantly
influenced by GH status only in men over 50 years.
No correlation between GH values and IGF-I/IGFBP-3
molar ratios indicates that GH concentrations in healthy
middle and old age subjects are not significantly influenced
by the changes in free IGF-I concentrations. This pheno-
menon will persist during middle and older because the
ratios of GH values to IGF-I/IGFBP-3 molar ratios also did
not show correlation with age in the present study.
The present study did not concomitantly determine the
serum sex hormones values. This makes us unable to evaluate
the actual impact of sex hormones on IGF-I, IGFBP-3 and
GH production. All blood sampling in female before meno-
pause were random without selection in any particular
menstrual phase. Serum IGF-I levels fluctuate with estrogen
levels during menstrual cycle, however, this fluctuation in
serum IGF-I levels is usually mild.
43
In conclusion, IGF-I progressively decrease with age,
which is not correlated with GH. Influence of aging on serum
concentrations of IGF-I is more remarkable in women than in
men. Menopause causes reduction of IGF-I/IGFBP-3 molar
ratio. Women have the trend of progressive hypoactivity of
GH to stimulate IGF-I and IGFBP-3 secretions with age.
This work was supported by Kaohsiung Medical University
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